Following a full submission.
Atazanavir (Reyataz) is accepted for restricted use within NHS Scotland for the treatment of HIV-1 infected, antiretroviral treatment experienced adults, in combination with other antiretroviral medicinal products in those patients who do not require concomitant statin use.
The combination of atazanavir and ritonavir was non-inferior to a standard boosted protease inhibitor (PI) regimen in patients with moderate previous exposure to PIs, however, it was inferior in patients with PI-resistant viruses. It was associated with lower incidences of diarrhoea and lipid adverse-effects and a higher incidence of hyperbilirubinaemia.
The health economic case for use is acceptable when atazanavir is compared with a standard boosted protease inhibitor regime in patients receiving concomitant statins.
Download detailed advice29KB (PDF)
- Medicine name:
- Atazanavir (Reyataz®)
- SMC ID:
- Pharmaceutical company
- Bristol-Myers Squibb Pharmaceuticals Ltd
- BNF chapter
- Submission type
- Date advice published
- 13 September 2004